

Daniel L. Gillen, Ph.D.

Assistant Professor
Department of Statistics, University of California, Irvine
346 Computer Science, Irvine, CA 92697
Email: dgillen@uci.edu
Phone: 949.824.9862 Fax: 949.824.9863

Research Interests

Survival analysis, longitudinal data analysis, clinical trials, sequential testing, epidemiologic methods

Education

1998-2003, Ph.D., Biostatistics, University of Washington, Seattle, WA.
1998-2001, M.S., Biostatistics, University of Washington, Seattle, WA.
1995-97, B.S., Mathematics, Cal Poly State University, San Luis Obispo, CA.

Positions

Academic Appointments

2004 - present, Assistant Professor, Department of Statistics, University of California, Irvine
2003 - 2004, Assistant Professor, Department of Health Studies, University of Chicago

Collaborative Research / Committees

August 1998 - 2003, Department of Nephrology, University of Washington and Puget Sound Healthcare System, Department of Veterans Affairs, Seattle, WA. Principal Investigator: Catherine Stehman-Breen, MD, MS
July 2001 - 2003, Coronary Artery Risk Development in Young Adults (CARDIA) Study, Renal Research Group, Seattle, WA. Principal Investigator: _____ MD, MPH
September 2001 - present, Cardiovascular Health Study (CHS), Renal Working Group, Seattle, WA. Principal Investigator: _____ MD, MPH
September 2003 - present, Nephrolithiasis Working Group, Chicago, IL. Principal Investigator: _____, MD
January 2005 - present, Genetic Epidemiology Research Institute (GERI), UC Irvine, CA. Principal Investigator: _____, MD PhD

Academic Awards and Scholarships

CORCLR Travel Award, University of California, Irvine (2005).
NIH Travel Award, International Biometrics Conference (Cairnes, AUS; 2004).
NIH Travel Award, ENAR Young Investigators Meeting (Pittsburgh, PA; 2004).
WNAR Student Paper Competition, "Information growth in a family of weighted logrank statistics under interim analyses", 1st place written paper, 1st place oral presentation (2003).
Outstanding Student in Biostatistics Award, School of Public Health, University of Washington (2003).
Donovan J. Thompson Award for excellence in applied and theoretical Biostatistics, Dept. of Biostatistics, University of Washington (2000).
NIH Cancer-Epidemiology-Biostatistics Training Grant (1999 - 2003).

Professional Memberships

American Statistical Association (2003-present)
International Biometric Society (2002-present)
American Society of Nephrology (2004-present)

Professional Services

Short-course Author: *American Society of Nephrology Annual Conference - Introduction to Biostatistics* (2000, 2001)

Short-course Author/Instructor: *Department of Nephrology, Puget Sound Healthcare System - An Introduction to SAS* (2001, 2002)

Reviewer:

Journal of the American Statistical Association
Biometrics
Lifetime Data Analysis
Sequential Analysis
Journal of Biopharmaceutical Statistics
Kidney International
Journal of the American Society of Nephrology

Appointments, Advisory Boards and Review Committees

Member, Data Safety Monitoring Committee, Chao Comprehensive Cancer Center, University of California, Irvine

Member, Data Safety Monitoring Committee, Multicenter Clinical Trial of _____

Member, Scientific Advisory Panel: NIH-PA-02-153: *Translational Research for the Prevention and Control of Diabetes*

Academic Service

Member, Graduate Policy Committee, Donald Bren School of Information and Computer Sciences, UCI (2004-05)

Member, Biostatistics Curriculum Committee, Program in Public Health, UCI

Member, Educational Policy Committee, Donald Bren School of Information and Computer Sciences, UCI (2005-06)

Lecturer, Hematology/Oncology Fellows' Research Series, UCI

Research

Published Work

1. Stehman-Breen C., **Gillen D.**, and Gipson D., "Prescription of hormone replacement therapy in postmenopausal women with renal failure." *Kidney International*, Vol. 56 (1999), pp. 2243-7.
2. Stehman-Breen C., Sherrard D., **Gillen D.**, and Caps M., "Determinants of type and timing of initial permanent hemodialysis vascular access." *Kidney International*, Vol. 57 (2000), pp. 639-45.
3. Alem A., Sherrard D., **Gillen D.**, Weiss N., Beresford S., Heckeberst S., Wong C., and Stehman-Breen C., "Increased risk of hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 396-9.
4. Wong C., Gipson D., **Gillen D.**, Emerson S., Koepsell T., Sherrard D., Watkins S., and Stehman-Breen C., "Anthropometric measures and risk of death in children with end-stage renal disease." *American Journal of Kidney Diseases*, Vol. 36, No. 4 (2000), pp. 811-9.

5. Stehman-Breen, C., Sherrard, D., Alem, A., **Gillen, D.**, Heckeber, S., Wong, C., Ball, A., and Weiss, N., "Risk factors for hip fracture among patients with end-stage renal disease." *Kidney International*, Vol. 58 (2000), pp. 2200-5.
6. Gibson K., Caps M., **Gillen D.**, Bergelin R., Primozech J., and Strandness D., "Identification of factors predictive of lower extremity vein graft thrombosis." *Journal of Vascular Surgery*, Vol. 33 (2001), pp. 24-31.
7. Gibson K., Caps M., Kohler T., Hatsukami T., **Gillen D.**, Aldassy M., Sherrard D., and Stehman-Breen C., "Assessment of a policy to reduce placement of prosthetic hemodialysis access." *Kidney International*, Vol. 59 (2001), pp. 2335-45.
8. Mazhar A., Johnson R., **Gillen D.**, Stivelman J., Ryan M., Davis C., and Stehman-Breen C., "Risk factors and mortality associated with calciphylaxis in end-stage renal disease." *Kidney International*, Vol. 60 (2001), pp. 324-32.
9. Gibson, K., **Gillen, D.**, Caps M., Kohler T., Sherrard D., and Stehman-Breen C., "Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study." *Journal of Vascular Surgery*, Vol. 34 (2001), pp. 694-700.
10. Seliger, S., Weiss, N., **Gillen, D.**, Kestenbaum, B., Ball, A., Sherrard, D., and Stehman-Breen, C., "HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients." *Kidney International*, Vol. 47 (2002), pp. 384-7.
11. Wong C., Hingorani S., **Gillen D.**, Sherrard D., Watkins S., Brandt J., Ball A., and Stehman-Breen C., "Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 630-7.
12. Fung F., Sherrard D., **Gillen D.**, Wong C., Kestenbaum B., Seliger S., Ball A., and Stehman-Breen C., "Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients." *American Journal of Kidney Diseases*, Vol. 40 (2002), pp. 307-14.
13. Kestenbaum B., **Gillen D.**, Sherrard D., Seliger S., Ball A., and Stehman-Breen C., "Calcium channel blocker use and mortality among patients with end-stage renal disease." *Kidney International*, Vol. 61 (2002), pp. 2157-64.
14. Ball A., **Gillen D.**, Sherrard D., Weiss N., Emerson S., Seliger S., Kestenbaum B., and Stehman-Breen, C., "The risk of hip fracture among dialysis and renal transplant recipients." *JAMA*, Vol. 288 (2002), pp. 3014-8.
15. Seliger S., **Gillen D.**, Longstreth W. Jr, Kestenbaum B., and Stehman-Breen C., "Elevated risk of stroke among patients with end-stage renal disease." *Kidney International*, Vol. 64 (2003), pp. 603-9.
16. Stehman-Breen C., **Gillen D.**, Steffes M., Jacobs D., Lewis C., Kiefe C., and Siscovick D., "Racial and gender differences in early onset renal disease among young adults - the Coronary Artery Risk Development in Young Adults (CARDIA) Study." *Journal of the American Society of Nephrology*, Vol. 14, No. 9 (2003), pp. 2352-7.
17. Wasse H., **Gillen D.**, Ball A., Kestenbaum B., Seliger S., Sherrard D., and Stehman-Breen C., "Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients." *Kidney International*, Vol. 64 (2003), pp. 1455-61.
18. Kestenbaum B., Seliger S., Easterling T., **Gillen D.**, Critchlow C., Stehman-Breen C., Schwartz S., "Cardiovascular and thromboembolic events following hypertensive pregnancy." *American Journal of Kidney Diseases*, Vol. 42 (2003), pp. 982-9.
19. Seliger S., **Gillen D.**, Tirschwell D., Wasse H., Kestenbaum B., Stehman-Breen C., "Risk Factors for incident stroke among patients with end-stage renal disease." *Journal of the American Society of Nephrology*, Vol. 14 (2003), pp. 2623-31.
20. Kestenbaum B., Seliger S., **Gillen D.**, Wasse H., Young B., Sherrard D., Weiss N., Stehman-Breen C., "Parathyroidectomy rates among United States dialysis patients: 1990-1999." *Kidney International*, Vol. 65 (2004), pp. 282-8.
21. Seliger S., Siscovick D., Stehman-Breen C., **Gillen D.**, Fitzpatrick A., Bleyer A., Kuller L., "Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study." *Journal of the American Society of Nephrology*, Vol. 15, No. 7 (2004), pp. 1904-11.
22. Jani A., Al-Qamari A., Sapra B., Krauz L., Awan A., Kocherginsky M., **Gillen D.**, "Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy." *Clinical Prostate Cancer*, Vol. 3, No. 1 (2004), pp. 43-8.
23. Mittalhenkle A., **Gillen D.**, Stehman-Breen C., "Increased risk of mortality associated with hip fracture in the dialysis population." *American Journal of Kidney Diseases*, Vol. 44 (2004), pp. 672-9.
24. Kestenbaum B., Andress D., Schwartz S., **Gillen D.**, Seliger S., Jadav P., Sherrard D., Stehman-Breen C., "Survival following parathyroidectomy among United States dialysis Patients." *Kidney International*, Vol. 66 (2004), pp. 2010-6.
25. Williams J., Javaid B., Kadambi P., **Gillen D.**, Harland R., Thistlewaite J., Garfinkel M., Foster P., Atwood W., Millis J., Meehan S., Josephson M., "Leflunomide for polyomavirus type BK nephropathy" *New England Journal of Medicine*, Vol. 352, pp. 1157-8.

26. Vokes T., **Gillen D.**, Lovett J., Favus M., "Comparison of T-scores from different skeletal sites in differentiating post-menopausal women with and without prevalent vertebral fractures" *Journal of Clinical Densitometry*, Vol. 8 (2005), pp. 206-15.
27. **Gillen D.** and Emerson S., "Information growth in a family of weighted logrank statistics under interim analyses" *Sequential Analysis*, Vol. 24 (2005), pp. 1-22.
28. **Gillen D.**, Worcester E., and Coe F., "Decreased renal function among adults with a history of nephrolithiasis: A study of NHANES III" *Kidney International*, Vol. 67 (2005), pp. 685-90.
29. **Gillen D.** and Emerson S., "A note on P -values under group sequential testing and nonproportional hazards" *Biometrics*, Vol. 61 (2005), pp. 546-51.
30. **Gillen D.**, Coe F., and Worcester E., "Nephrolithiasis and increased blood pressure among females with increased BMI" *American Journal of Kidney Diseases*, Vol. 46 (2005), pp. 263-9.
31. Emerson S., Kittelson J., and **Gillen D.**, "Bayesian evaluation of group sequential clinical trial designs" (*In press, Statistics In Medicine*).
32. Santry H., **Gillen D.**, and Lauderdale D., "Trends in bariatric surgical procedures" *JAMA*, Vol. 294 (2005), pp. 1909-17.
33. Seliger S., Longstreth W., Katz R., Manolio T., Fried L., Shlipak M., Stehman-Breen C., Newman A., Sarnak M., **Gillen D.**, Bleyer A., Siscovick D., "Cystatin C and Subclinical Brain Infarction" *Journal of the American Society of Nephrology*, E-published.
34. Fried L., Katz R., Sarnak M., Shlipak M., Chaves P., Jenny N., Stehman-Breen C., **Gillen D.**, Bleyer A., Hirsch C., Siscovick D., Newman AB., "Kidney function as a predictor of noncardiovascular mortality" *Journal of the American Society of Nephrology*, E-published.
35. **Gillen D.** and Emerson S., "Non-transitivity in a class of weighted logrank statistics under nonproportional hazards" (*Revised and resubmitted, Statistics and Probability Letters*).


Work Submitted For Publication

Emerson S., Kittelson J., and **Gillen D.**, "Frequentist evaluation of group sequential clinical trial designs"

Emerson S., Kittelson J., and **Gillen D.**, "On the use of stochastic curtailment in group sequential clinical trial designs"

Gillen D. and Emerson S., "The evaluation of a clinical trial in the presence of nonproportional hazards".

Work In Progress



Teaching

Course Development

University of California, Irvine

Statistical Methods II (STAT 211): The second quarter of a three quarter sequence in the theory and application of statistical methods for graduate students in statistics. This course covers the theory and application of generalized linear models. First offered Winter, 2005.

Introduction to Probability & Statistics III (STAT 120C): The third quarter of a three quarter sequence in mathematical statistics for upper division undergraduate students. This course develops the theory behind ANOVA, linear regression, and categorical data methods. First offered Spring, 2005.

Biostatistics (STAT 250): A one quarter course in the theory and application of statistical methods commonly used in public health research. The course content is geared towards first year graduate students in statistics. First offered Fall, 2006.

Formal Teaching

University of California, Irvine

Stat 120C – Introduction to Probability & Statistics III : Spring 2005 & 2006, Department of Statistics, University of California, Irvine.

Stat 211 – Statistical Methods II : Winter 2005 & 2006, Department of Statistics, University of California, Irvine.

Stat 250 – Biostatistics : Fall 2006, Department of Statistics, University of California, Irvine.

University of Chicago

HSD 324 – Survival Analysis : Spring 2004, Departments of Health Studies and Statistics, University of Chicago.

Clinical Research Training Program : Fall/Winter/Spring 2003-04, Departments of Health Studies and Statistics, University of Chicago.

California Polytechnic University, San Luis Obispo

Math 116 – College Algebra : Winter/Spring 1998, Department of Mathematics, Cal Poly State University, San Luis Obispo.

Math 100 – Beginning/Intermediate Algebra : Fall/Winter/Spring 1996 - 1998, Student Academic Services, Cal Poly State University, San Luis Obispo.

Math 116 – College Algebra : Summer 1996-97, Summer Institute, Cal Poly State University, San Luis Obispo.

Invited Talks and Seminars

1. Vanderbilt University, Department of Biostatistics, "A random walk approach to the design and monitoring of group sequential trials" (Nashville, TN; Oct 2005)
2. Joint Statistical Meetings, Session Chair - "Bayesian hierarchical modeling in biostatistics" (Minneapolis, MN; Aug 2005).
3. NIH, NIAID, "Evaluation and monitoring of groups sequential trials under nonproportional hazards" (Washington, DC; July 2005).
4. WNAR, "The design and analysis of group sequential survival trials: A random walk approach" (Fairbanks, AK; Jun 2005).
5. California Association of Regional Cancer Registries (CARCR) Research Symposium, "Methods for modeling time-varying covariate effects in cohort studies" (Newport Beach, CA; February 2005)
6. University of California, Los Angeles, Department of Biostatistics, "A random walk approach to the design and monitoring of group sequential trials" (Los Angeles, CA; Feb 2005)
7. Brown University, Center for Statistical Sciences, "Issues in the design and analysis of group sequential survival trials" (Providence, RI; Nov 2004)
8. University of California, Irvine, Division of Epidemiology, "A joint longitudinal and survival model for flexibly incorporating nonproportional hazards" (Irvine, CA; Nov 2004).
9. Claremont McKenna College, Department of Mathematics, "When is enough, enough? The use of group sequential methods in clinical trials" (Claremont, CA; Oct 2004)
10. University of Wisconsin, Madison, Department of Biostatistics and Medical Informatics, "The use of weighted logrank statistics in group sequential trials" (Madison, WI; Apr 2004)
11. American Society of Nephrology, Invited lecture, "Perils and pitfalls in estimating renal function" (San Diego, CA; Nov 2003).
12. WNAR, Panel discussion on *Effective Teaching Practices* (Los Angeles, CA; Jun 2002).

Contributed Presentations at National Meetings

1. Joint Statistical Meetings, "A joint longitudinal and survival model for flexibly incorporating nonproportional hazards" (Toronto, CAN; Aug 2004).
2. International Biometric Conference, "Estimation of fixed time survival via random walks" (Cairnes, AUS; Jul 2004).
3. Joint Statistical Meetings, "Evaluating a clinical trial in the presence of non-proportional hazards" (San Francisco, CA; Aug 2003).
4. WNAR, "Information growth in a family of weighted logrank statistics under interim analyses" (Golden, CO; Jun 2003).
5. WNAR, "Non-transitivity in a class of weighted logrank statistics under non-proportional hazards" (Los Angeles, CA; Jun 2002).

**APPEARS THIS WAY
ON ORIGINAL**